文献速递肝病

血清血管生成素-2可预测失代偿期肝硬化患者的死亡率和肾脏结局

Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis.
PubMed 文献 · Hepatology · 2019-01-04

本研究在前瞻性队列的191例失代偿期肝硬化合并急性肾损伤住院患者中连续检测血清血管生成素-2,发现其水平升高与90天死亡率、更高的急性肾损伤网络分期及需要肾脏替代治疗相关,且在MELD评分基础上可改善对死亡率的判别能力。

要点

  • 血清血管生成素-2水平升高与失代偿期肝硬化合并急性肾损伤患者的90天死亡率增加相关。
  • 血管生成素-2水平随急性肾损伤网络分期加重而升高,并与需要肾脏替代治疗相关。
  • 在MELD评分基础上加入血管生成素-2可改善对死亡率的判别能力。

核心结论

  • 在失代偿期肝硬化合并急性肾损伤的患者队列中,血管生成素-2与死亡率及其他临床相关结局相关。
  • 需要进一步开展实验研究探索血管生成素/Tie2信号通路在该人群中的潜在机制和治疗作用。

研究设计与样本

  • 前瞻性队列研究,连续纳入失代偿期肝硬化合并急性肾损伤的住院患者191例,连续检测血清血管生成素-2,随访90天。

主要发现

  • 患者中位血管生成素-2水平为18.2(四分位距11.8,26.5)ng/mL,中位MELD评分为23(17,30),90天死亡率为41%。
  • 死亡患者血管生成素-2水平为21.9(13.9,30.3)ng/mL,存活患者为15.2(9.8,23.0)ng/mL,P < 0.001。
  • 急性肾损伤网络I期患者血管生成素-2水平为13.4(9.8,20.1)ng/mL,II期为20.0(14.1,26.2)ng/mL,III期为21.9(13.0,29.5)ng/mL,P = 0.002。
  • 需要肾脏替代治疗的患者血管生成素-2水平为25.1(13.3,30.3)ng/mL,不需要者为16.5(11.3,23.6)ng/mL,P = 0.005。
  • 血管生成素-2与死亡率的关联在未调整和调整的Cox回归模型中均有统计学意义(所有模型P ≤ 0.001),在MELD评分基础上加入血管生成素-2可改善对死亡率的判别能力(综合判别改善指数0.067;P = 0.001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute kidney injury in decompensated cirrhosis has limited therapeutic options, and novel mechanistic targets are urgently needed. Angiopoietin-2 is a context-specific antagonist of Tie2, a receptor that signals vascular quiescence. Considering the prominence of vascular destabilization in decompensated cirrhosis, we evaluated Angiopoietin-2 to predict clinical outcomes. Serum Angiopoietin-2 was measured serially in a prospective cohort of hospitalized patients with decompensated cirrhosis and acute kidney injury. Clinical characteristics and outcomes were examined over a 90-day period and analyzed according to Angiopoietin-2 levels. Primary outcome was 90-day mortality. Our study included 191 inpatients (median Angiopoietin-2 level 18.2 [interquartile range 11.8, 26.5] ng/mL). Median Model for End-Stage Liver Disease (MELD) score was 23 [17, 30] and 90-day mortality was 41%. Increased Angiopoietin-2 levels were associated with increased mortality (died 21.9 [13.9, 30.3] ng/mL vs. alive 15.2 [9.8, 23.0] ng/mL; P < 0.001), higher Acute Kidney Injury Network stage (stage I 13.4 [9.8, 20.1] ng/mL vs. stage II 20.0 [14.1, 26.2] ng/mL vs. stage III 21.9 [13.0, 29.5] ng/mL; P = 0.002), and need for renal replacement therapy (16.5 [11.3, 23.6] ng/mL vs. 25.1 [13.3, 30.3] ng/mL; P = 0.005). The association between Angiopoietin-2 and mortality was significant in unadjusted and adjusted Cox regression models (P ≤ 0.001 for all models), and improved discrimination for mortality when added to MELD score (integrated discrimination increment 0.067; P = 0.001). Conclusion: Angiopoietin-2 was associated with mortality and other clinically relevant outcomes in a cohort of patients with decompensated cirrhosis with acute kidney injury. Further experimental study of Angiopoietin/Tie2 signaling is warranted to explore its potential mechanistic and therapeutic role in this population.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Allegretti AS, Vela Parada X, Ortiz GA, et al. Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis. Hepatology. 2019. PMID: 30141205. doi:10.1002/hep.30230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。